ArticlePloS one2012
New insights into the role of MHC diversity in devil facial tumour disease.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Improved high-throughput MHC typing for non-model species using long-read sequencing.Molecular ecology resources · 2022Pooled it
- Boost or Bust? The Impact of Supplementation on Functional Genetic Diversity and Selective Processes in Tasmanian Devils.Molecular ecology · 2025Article
- Using bioinformatics to investigate functional diversity: a case study of MHC diversity in koalas.Immunogenetics · 2024Article
- Two Decades of the Impact of Tasmanian Devil Facial Tumor Disease.Integrative and comparative biology · 2018Article
- Article
- The devil is in the details: Genomics of transmissible cancers in Tasmanian devils.PLoS pathogens · 2018Article
- MHC diversity and female age underpin reproductive success in an Australian icon; the Tasmanian Devil.Scientific reports · 2018Article
- Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release.Frontiers in immunology · 2018Article
- The role of MHC genes in contagious cancer: the story of Tasmanian devils.Immunogenetics · 2017Review
- Variants in the host genome may inhibit tumour growth in devil facial tumours: evidence from genome-wide association.Scientific reports · 2017Article
- Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils.Scientific reports · 2017Article
- A second transmissible cancer in Tasmanian devils.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Transmissible cancer in Tasmanian devils: localized lineage replacement and host population response.Proceedings. Biological sciences · 2015Article
- Immunology of naturally transmissible tumours.Immunology · 2015Article
- Using genomics to characterize evolutionary potential for conservation of wild populations.Evolutionary applications · 2014Article
- Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Evolution of a contagious cancer: epigenetic variation in Devil Facial Tumour Disease.Proceedings. Biological sciences · 2013Article
- MHC class II DQB diversity in the Japanese black bear, Ursus thibetanus japonicus.BMC evolutionary biology · 2012Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDevil facial tumour disease (DFTD) is a fatal contagious cancer that has decimated Tasmanian devil populations. The tumour has spread without invoking immune responses, possibly due to low levels of Major Histocompatibility Complex (MHC) diversity in Tasmanian devils. Animals from a region in north-western Tasmania have lower infection rates than those in the east of the state. This area is a genetic transition zone between sub-populations, with individuals from north-western Tasmania displaying greater diversity than eastern devils at MHC genes, primarily through MHC class I gene copy number variation. Here we test the hypothesis that animals that remain healthy and tumour free show predictable differences at MHC loci compared to animals that develop the disease. METHODOLOGY/PRINCIPAL
findingsWe compared MHC class I sequences in 29 healthy and 22 diseased Tasmanian devils from West Pencil Pine, a population in north-western Tasmania exhibiting reduced disease impacts of DFTD. Amplified alleles were assigned to four loci, Saha-UA, Saha-UB, Saha-UC and Saha-UD based on recently obtained genomic sequence data. Copy number variation (caused by a deletion) at Saha-UA was confirmed using a PCR assay. No association between the frequency of this deletion and disease status was identified. All individuals had alleles at Saha-UD, disproving theories of disease susceptibility relating to copy number variation at this locus. Genetic variation between the two sub-groups (healthy and diseased) was also compared using eight MHC-linked microsatellite markers. No significant differences were identified in allele frequency, however differences were noted in the genotype frequencies of two microsatellites located near non-antigen presenting genes within the MHC. CONCLUSIONS/SIGNIFICANCE: We did not find predictable differences in MHC class I copy number variation to account for differences in susceptibility to DFTD. Genotypic data was equivocal but indentified genomic areas for further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.